
Lumos Diagnostics CEO Doug Ward joined Steve Darling from Proactive to discuss the expanding commercial rollout of the company's FebriDx rapid diagnostic test, with deployment now underway at more than 30 U.S. urgent care sites and three additional major healthcare groups advancing through clinical and economic validation. Together, the four priority healthcare accounts represent more than 430 potential locations and an estimated 2.6 million acute respiratory infection patient visits annually, supporting Lumos' strategy of targeting the 100 largest U.S. urgent care groups, which account for roughly 40% of all urgent care sites nationwide. One of the company's latest customers, a leading regional urgent care provider owned by a major U.S. health system, has agreed to deploy FebriDx across its network of more than 30 clinics. Lumos estimates the network treats approximately 200,000 acute respiratory infection cases each year, where FebriDx is expected to improve respiratory triage,...
Loading summary